(VIANEWS) – Templeton Global Income Fund (GIM), Pfizer (PFE), Eaton Vance Municipal Income Trust (EVN) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio up to now. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Templeton Global Income Fund (GIM)
204.44% Payout Ratio
Templeton Global Income Fund is a closed-ended fixed income mutual fund launched by Franklin Resources, Inc. It is managed by Franklin Advisers, Inc. The fund invests in fixed income markets across the globe. It primarily invests in government bonds. The fund is actively managed. It benchmarks the performance of its portfolio against the J.P. Morgan Global Government Bond Index. Templeton Global Income Fund was formed on March 17, 1988 and is domiciled in the United States.
Earnings Per Share
As for profitability, Templeton Global Income Fund has a trailing twelve months EPS of $0.18.
PE Ratio
Templeton Global Income Fund has a trailing twelve months price to earnings ratio of 21.22. Meaning, the purchaser of the share is investing $21.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.6%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Dec 14, 2023, the estimated forward annual dividend rate is 0.35 and the estimated forward annual dividend yield is 9.05%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 36.7%, now sitting on 28.58M for the twelve trailing months.
Moving Average
Templeton Global Income Fund’s worth is below its 50-day moving average of $3.94 and below its 200-day moving average of $4.10.
2. Pfizer (PFE)
89.07% Payout Ratio
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Pfizer has a trailing twelve months EPS of $1.83.
PE Ratio
Pfizer has a trailing twelve months price to earnings ratio of 16.5. Meaning, the purchaser of the share is investing $16.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.06%.
3. Eaton Vance Municipal Income Trust (EVN)
85.18% Payout Ratio
Eaton Vance Municipal Income Trust is a close ended fixed income mutual fund launched and managed by Eaton Vance Management. It invests in the fixed income markets. The fund invests primarily in investment grade municipal obligations of various sectors, such as cogeneration, education, electric utilities, general obligations, healthcare, hospital, housing, transportation, and nursing home. Eaton Vance Municipal Income Trust was formed in 1998 and is domiciled in United States.
Earnings Per Share
As for profitability, Eaton Vance Municipal Income Trust has a trailing twelve months EPS of $-0.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.9%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 7, 2023, the estimated forward annual dividend rate is 0.45 and the estimated forward annual dividend yield is 4.53%.
4. United-Guardian (UG)
74.55% Payout Ratio
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products in the United States and internationally. It offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. The company's medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. Its pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. The company's industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. It also conducts research and development primarily related to the development of cosmetic ingredients. The company markets its products through marketing partners, distributors, and wholesalers. United-Guardian, Inc. was founded in 1942 and is based in Hauppauge, New York.
Earnings Per Share
As for profitability, United-Guardian has a trailing twelve months EPS of $0.55.
PE Ratio
United-Guardian has a trailing twelve months price to earnings ratio of 12.93. Meaning, the purchaser of the share is investing $12.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.42%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
United-Guardian’s EBITDA is 2.2.
Moving Average
United-Guardian’s worth is below its 50-day moving average of $7.40 and way under its 200-day moving average of $8.18.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 24, 2023, the estimated forward annual dividend rate is 0.41 and the estimated forward annual dividend yield is 5.82%.
Yearly Top and Bottom Value
United-Guardian’s stock is valued at $7.11 at 07:23 EST, way under its 52-week high of $12.51 and way higher than its 52-week low of $5.79.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1%.
Sales Growth
1’s sales growth is 1% for the ongoing quarter and 1% for the next.
